Cardiovascular safety of PDE5 inhibitors
Sender Herschorn
Canadian Journal of Urology, Vol.10, Suppl.1, pp. 23-28, 2003
Abstract Erectile dysfunction (ED) and cardiovascular disease
share many of the same risk factors and have some
common elements of pathophysiology. Clinically, they
often coexist. Another link between the two conditions
is that sildenafil, the first oral therapeutic agent effective
in treating ED, has been shown to potentiate the
hypotensive effects of nitrates, a potentially serious side
effect. Nitrates are commonly used in the treatment of
coronary artery disease. As such, sildenafil (and, likely,
other new phosphodiesterase type 5 [PDE5] inhibitors)
is contraindicated in men who use nitrate medications.
This article will examine the risk of More >
Login
Register
Submit a Paper
Propose a Special lssue